Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 28.68% is 28% above its 5-year average of 22.42%, near the high end of its 5-year range (4.61%–32.02%).
As of the fiscal period ended Tuesday, June 30, 2026. 62.91% above its 12-month average of 17.61%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 28.68%.
DEBT TO ASSETS RATIO
28.68%
DEBT TO ASSETS RATIO AVG TTM
17.61%
DEBT TO ASSETS RATIO AVG 3Y
22.45%
DEBT TO ASSETS RATIO AVG 5Y
22.42%
DEBT TO ASSETS RATIO AVG 10Y
14.28%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+62.91%
CURRENT VS 3Y AVG
+27.75%
CURRENT VS 5Y AVG
+27.95%
CURRENT VS 10Y AVG
+100.79%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 868 covered companies
CURRENT VS SECTOR MEDIAN
+31767.51%
vs the sector median at left
Cue Biopharma, Inc.
Market Cap
$171.06M
Debt to Assets Ratio
28.68%
TTM Avg
17.61%
3Y Avg
22.45%
5Y Avg
22.42%
Market Cap
$169.90M
Debt to Assets Ratio
0.22%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$169.85M
Debt to Assets Ratio
0.16%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$173.39M
Debt to Assets Ratio
0.26%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$173.76M
Debt to Assets Ratio
0.10%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$174.88M
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | $171.06M | 28.68% | 17.61% | 22.45% | 22.42% |
| Precision BioSciences, Inc. (DTIL)vs › | $169.90M | 0.22% | N/A | N/A | N/A |
| Organogenesis Holdings Inc. (ORGO)vs › | $169.85M | 0.16% | N/A | N/A | N/A |
| Journey Medical Corporation (DERM)vs › | $173.39M | 0.26% | N/A | N/A | N/A |
| ProQR Therapeutics N.V. (PRQR)vs › | $173.76M | 0.10% | N/A | N/A | N/A |
| MediWound Ltd. (MDWD)vs › | $168.02M | 0.13% | N/A | N/A | N/A |
| Compass Therapeutics, Inc. (CMPX)vs › | $174.88M | 0.05% | N/A | N/A | N/A |
| Nkarta, Inc. (NKTX)vs › | $166.70M | 0.22% | N/A | N/A | N/A |
| OptimizeRx Corp. (OPRX)vs › | $165.60M | 0.12% | N/A | N/A | N/A |
| Quanterix Corporation (QTRX)vs › | $164.16M | 0.10% | N/A | N/A | N/A |
Debt/Assets
28.7%
Debt/Equity
3.81
Current Ratio
1.25
Interest Coverage
-74.3x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 28.68% |
| 2026-03-31 | 11.14% |
| 2025-12-31 | 9.94% |
| 2025-09-30 | 19.51% |
| 2025-06-30 | 18.75% |
| 2025-03-31 | 32.02% |
| 2024-12-31 | 27.57% |
| 2024-09-30 | 21.23% |
| 2024-06-30 | 26.61% |
| 2024-03-31 | 24.09% |
| 2023-12-31 | 23.88% |
| 2023-09-30 | 23.77% |
| 2023-06-30 | 24.66% |
| 2023-03-31 | 22.90% |
| 2022-12-31 | 21.16% |
| 2022-09-30 | 30.07% |
| 2022-06-30 | 23.44% |
| 2022-03-31 | 22.06% |
| 2021-12-31 | 14.41% |
| 2021-09-30 | 4.61% |
| 2021-06-30 | 5.44% |
| 2021-03-31 | 6.85% |
| 2020-12-31 | 7.18% |
| 2020-09-30 | 7.69% |
| 2020-06-30 | 8.32% |
| 2020-03-31 | 7.76% |
| 2019-12-31 | 8.09% |
| 2019-09-30 | 15.58% |
| 2019-06-30 | 18.74% |
| 2019-03-31 | 19.01% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 3.89% |
| 2017-12-31 | 3.73% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2016-12-31 | 0.00% |
